PP2R1A逆转录病毒的构建及对细胞周期的影响

目的：构建重组PP2R1A基因的逆转录病毒感染HEKTER细胞,观察其定位,验证表达,研究过表达PP2R1A对细胞生长及周期的影响。方法：逆转录病毒载体pMIG-Flag-PP2R1A-IRES-GFP与Pcll0A1瞬时共转染293T细胞,收集病毒感染HEKTER细胞,在荧光显微镜下观察定位,标记荧光单克隆。挑取不同表达强度单克隆做western验证PP2R1A蛋白表达。运用流式细胞分析、体外创伤试验及生长曲线试验研究单克隆细胞的增殖及周期。结果：获得了过表达PP2R1A的单克隆细胞株,PP2R1A在细胞内广泛表达,结合western及细胞试验证实PP2R1A高表达阻滞细胞周期并减慢细胞生长。结论：PP2R1A是丝苏氨酸蛋白磷酸酶PP2A的结构A亚基的a亚型,在细胞内广泛表达。本文成功构建了表达PP2R1A的细胞株,研究发现PP2R1A高表达会影响细胞生长及细胞周期,减缓了细胞增殖。为进一步深入研究PP2R1A对PP2A全酶活性及功能、细胞转化的影响奠定了重要的实验基础。     

蛋白磷酸酶2A的结构、功能和活性调节

蛋白磷酸酶 2A(proteinphosphatase 2A ,PP2A)是主要的丝 /苏氨酸蛋白磷酸酶 ,拥有众多不同基因编码的亚基 ,分别组成多种不同的PP2A全酶 ,参与细胞周期、DNA复制、信号转导、细胞分化和细胞恶性转化等多种细胞生物学事件 ,并和神经退行性疾病、肿瘤等多种疾病的发生、发展有关。PP2A调节亚基的组织特异性表达和细胞内定位 ,催化亚基羧基末端的磷酸化和甲基化 ,第二信使神经酰胺 (ceramide)、天然小分子抑制剂等都能够调节PP2A的活性。     

基于逆转录病毒载体构建稳定表达人CD19和荧光蛋白的SW620细胞株

摘要 目的：构建表达人CD19和增强型绿色荧光蛋白（EGFP）和荧光素酶（LUC）的SW620细胞株。方法：构建MFG-CD19质粒,进行逆转录病毒载体包装,与MFG-EGFP-P2A-LUC逆转录病毒载体共同转导SW620细胞,筛选出稳定且强表达的单克隆细胞株SW620-CD19-EGFP-LUC并扩大培养。通过流式细胞术与qPCR技术检测细胞CD19的表达、通过荧光素酶法对细胞系表面荧光素酶的表达和细胞系功能进行鉴定。结果：流式检测构建完成的细胞株中CD19阳性的细胞占比为99.9%,EGFP阳性的细胞占比为99.2%;荧光显微镜下能够明显观察到细胞的绿色荧光;qPCR检测结果表明细胞株中CD19的表达水平相比原始细胞株明显上调,并且能够激活CD19 CAR-T细胞对其进行杀伤。结论：成功构建了能够稳定表达人CD19和荧光蛋白的SW620细胞株。     

沉默DEPDC1基因表达对鼻咽癌细胞系HNE-1生长和细胞周期的影响

为探讨沉默DEPDC,基因表达对鼻咽癌细胞系HNE．1生长和细胞周期的影响,该实验设计合成靶向DEPDCl的小分子干扰RNA（smallinterferingRNA,siRNA）转染人鼻咽癌HNE-1细胞。转染后,采用荧光定量PCR、免疫印迹、MTT及流式细胞术方法检测细胞内DEPDCl的表达量以及细胞周期、生长增殖、凋亡的变化及其可能机制。结果显示,转染DEPDClsiRNA后,DEPDC1基因在mRNA及蛋白水平的表达量明显降低;大量细胞被阻滞于G2／M期,生长增殖减慢,凋亡增加。荧光定量PCR结果表明,抑制NF—KB激活的A20基因表达量明显上调,受NF-κB调控的肿瘤相关靶基因的表达量下降,包括C-MYC、MMP9、ICAM-1、BCL-2基因。由此说日月,沉默DEPDC1基因可以影响HNE-1细胞的周期,抑制其生长增殖,促进凋亡,其机制可能与抑制NF-κB通路有关。     

rBTI通过上调PTEN的表达抑制Hep G2细胞增殖

磷酸酶及张力蛋白的同源基因(PTEN) 是一种抑癌基因,可以调控细胞的增殖,与癌症的发生和发展息息相关。本研究采用MTT法和流式细胞术分别检测了重组荞麦胰蛋白酶抑制剂(rBTI)对人肝癌细胞株Hep G2细胞的增殖以及周期的影响。免疫荧光及Western印迹法检测了PTEN和p PTEN的亚细胞定位及蛋白表达的变化。采用qRT-PCR及Western印迹法检测了周期相关蛋白的表达。旨在探究PTEN和p PTEN在rBTI抑制Hep G2细胞增殖和周期阻滞中的作用。结果表明,rBTI能显著抑制Hep G2细胞增殖,将细胞周期阻滞在G0/G1期,并呈时间和剂量依赖性;rBTI作用于Hep G2后,可显著上调PTEN和p-PTEN的表达。同时发现,p-PTEN主要分布于细胞核中,能与核仁发生共定位;周期相关蛋白检测表明,细胞内p53、p21转录水平和蛋白水平均增加。综上所述,rBTI通过上调PTEN的表达,使得细胞周期阻滞于G0/G1期,进而抑制Hep G2细胞的增殖。     

PP2A通过Akt/Skp2通路调控p27~(Kip1)的表达并抑制肺癌细胞的致瘤能力

蛋白磷酸酶2A(PP2A)是由36 k Da的催化亚基C(PP2Ac)和65 k Da的结构亚基A(PP2Aα/β)一起组成PP2A的核心酶,并且和各种不同的调节亚基B形成具有不同功能的PP2A全酶复合体。在细胞中PP2A发挥着重要作用,特别是在抑制肿瘤的形成当中,编码PP2Aα/β基因的突变将导致肿瘤的形成和其他疾病。当非小细胞肺癌细胞H1299中过表达PP2A-Aα时,细胞生长被抑制,细胞周期停留在G0/G1期,致瘤能力也同时被抑制。进一步研究证明当PP2A-Aα过表达时,Akt被去磷酸化失活使Skp2的表达下调,从而导致细胞周期抑制因子p27kip1的表达上调。肿瘤细胞软琼脂克隆形成实验的结果表明过表达PP2A-Aα之后H1299细胞的锚定非依赖性生长能力明显的降低,形成的克隆细胞团也较小,这些结果和裸鼠成瘤实验的结果是一致的。     

原钙黏蛋白7b与绿色荧光蛋白融合基因表达载体的构建及其在MCF10A细胞中的表达定位

目的:构建原钙黏蛋白7b(PCDH7b)与绿色荧光蛋白(GFP)的融合基因表达载体pQCXIP-PCDH7b-EGFP,并检测PCDH7b-GFP融合蛋白在细胞中的表达定位。方法:以MDA-MB-436细胞基因组DNA为模板,PCR扩增人PCDH7b基因,克隆入逆转录病毒载体pQCXIP-EGFP-N1构建pQCXIP-PCDH7b-EGFP,病毒包装后感染人乳腺上皮细胞系MCF10A,免疫荧光染色检测其与膜蛋白E钙黏蛋白的相对表达定位。结果:构建获得逆转录病毒载体pQCXIP-PCDH7b-EGFP,融合蛋白PCDH7b-GFP定位于细胞浆和细胞膜,与E钙黏蛋白有共定位。结论:PCDH7b-GFP融合蛋白的表达,为后续活细胞成像分析PCDH7b在细胞内的动态分布奠定了基础。     

HRB2慢病毒表达质粒的构建核蛋白细胞内定位的研究

目的:构建重组HIV-1相关结合蛋白2(HIV-1 rev binding protein 2)基因的真核融合表达质粒plenti-OFP-HRB2,用慢病毒表达系统感染HEKTER细胞.对过表达GFP-HRB2基因的细胞在激光共聚焦显微镜下观察,研究HRB2蛋白在细胞中的分布规律.方法:Trizol法提取人睾丸组织总RNA进行RT-PCR,将纯化的扩增产物HRB2与克隆载体plp-GFP-Cl连接、转化感受态细菌E.coli XLblue.测序正确后将质粒plp-GFP-HRB2与真核表达质粒plenti-Cl分别进行双酶切,连接后转化.将构建正确的plenti-GFP-HRB2重组质粒、△8.91、pvsvg瞬时共转染293T细胞后,用荧光显微镜观察绿色荧光蛋白的表达.收集包装病毒后感染HEKTER细胞.细胞生长一周后,将细胞铺玻片上用激光共聚焦显微镜观察.结果:构建的plenti-GFP-HRB2真核表达质粒经PCR鉴定及测序均说明人源HRB2基因已与plenti-GFP载体正确重组.瞬时转染293T细胞后能观察到绿色荧光.稳定感染后的HEKTER细胞经激光共聚焦显微镜观察后发现,HRB2蛋白在核仁处富集,在细胞核的其它部位少量分布,在胞浆中几乎没有分布.结论:人源HRB2基因表达的相关蛋白具有一个KH结构域,属于KH结构域家族的成员.稳定表达GFP-HRB2融合蛋白的细胞系的成功构建,为深入研究HRB2的入核机制、HRB2蛋白的在细胞分裂、RNA剪切等生物活动中的作用奠定了重要的实验基础.     

小干扰RNA抑制LRP16基因表达限制了MCF-7乳腺癌细胞增殖

雌激素雌二醇上调人乳腺癌细胞MCF 7中LRP16基因表达 ,该基因过表达促进MCF 7细胞增殖 .为进一步探讨LRP16基因不同表达水平对MCF 7细胞增殖的影响以及对雌激素的反应性增殖能力 ,采用针对LRP16基因特异的小干扰RNA策略 ,通过逆转录病毒介导及抗性筛选构建了LRP16基因被稳定抑制的 2个MCF 7细胞系 ,针对绿色荧光蛋白的干扰序列作为阴性对照 .Northern印迹实验检测了LRP16基因在各个细胞株中mNRA的水平 ,与对照组细胞比较 ,针对LRP16基因不同位置的 2个小干扰RNA可分别将该基因抑制 90 %和 6 0 % .细胞增殖试验结果显示 ,MCF 7细胞中LRP16基因表达抑制率越高 ,细胞增殖速率减慢越显著 (P <0 0 5 ) ;软琼脂集落形成试验结果显示 ,抑制LRP16基因在MCF 7细胞中表达 ,限制了细胞锚定非依赖性生长 ;细胞周期分析结果表明 ,LRP16基因抑表达使MCF 7细胞G1 S周期转换受抑 ;Western印迹结果表明 ,LRP16基因表达抑制的细胞中细胞周期蛋白E及细胞周期蛋白D1蛋白水平显著下调 ,但未检测到P5 3及Rb蛋白表达水平的影响 .雌二醇刺激的增殖实验结果显示 ,抑制LRP16基因表达没有消除MCF 7细胞的反应性增殖特征 .上述结果表明 ,LRP16基因表达量与MCF 7细胞增殖能力密切相关 ,抑制其表达可有效限制MCF 7细胞的增殖能力 ,提     

共表达口蹄疫病毒衣壳前体蛋白P1-2A基因和蛋白酶3C基因牛肾细胞株的筛选及稳定性

[目的]筛选稳定表达口蹄疫病毒衣壳蛋白的牛肾细胞(Madin-Darby bovinekidney,MDBK)株.[方法]采用聚合酶链式反应(Polymerase chain reaction,PCR)方法从重组质粒pMD-P1-2A和pMD-3C中分别扩增口蹄疫病毒衣壳前体蛋白P1-2A基因和蛋白酶3C基因,将两基因依次插入逆转录病毒载体pBABE-puro.重组逆转录病毒载体pBABE-puro/P1-2A-3C和pVSV-G质粒载体用脂质体介导共转染GP2-293包装细胞.产生的重组逆转录病毒感染MDBK细胞后使用嘌呤霉素筛选抗性细胞.利用克隆环套取法得到单克隆细胞.经间接免疫荧光和酶联免疫吸附测定(Enzyme-linkedimmunosorbent assay,ELISA)方法检测MDBK细胞中衣壳蛋白的表达,并在电镜下观察口蹄疫病毒空衣壳.[结果]成功筛选到稳定表达口蹄疫病毒衣壳蛋白的MDBK细胞株,衣壳前体蛋白P1-2A在蛋白酶3C裂解作用下正确组装成空衣壳.[结论]该研究为口蹄疫亚单位疫苗的研制提供了实验材料.     

Adenosine A1 and A2A receptor regulation of protein phosphatase 2A in the murine heart

Adenosine plays a role in regulating the contractile function of the heart. This includes a positive ionotropic action via the adenosine A(2A) receptor (A(2A)R) and an inhibition of beta(1)-adrenergic receptor-induced ionotropy (antiadrenergic action) via the adenosine A(1) receptor (A(1)R). Phosphatase activity has also been shown to influence contractile function by affecting the level of protein phosphorylation. Protein phosphatase 2A (PP2A) plays a significant role in mediating the A(1)R antiadrenergic effect. The purpose of this study was to investigate the effects of A(2A)R and A(1)R on the activities of PP2A in hearts obtained from wild-type (WT) and A(2A)R knockout (A(2A)R-KO) mice. PP2A activities were examined in myocardial particulate and cytoplasmic extract fractions. Treatment of wild-type hearts with the A(1)R agonist CCPA increased the total PP2A activity and increased the particulate:cytoplasmic PP2A activity ratio. Treatment with the A(2A)R agonist CGS-21680 (CGS) decreased the total PP2A activity and decreased the particulate:cytoplasmic PP2A activity ratio. This indicated a movement of PP2A activity between cell fractions. The effect of CCPA was inhibited by CGS. In A(2A)R-KO hearts the response to A(1)R activation was markedly enhanced whereas the response to A(2A)R activation was absent. These data show that A(2A)R and A(1)R regulate PP2A activity, thus suggesting an important mechanism for modulating myocardial contractility.     

Protein phosphatase 2A modulates the proliferation of human multiple myeloma cells via regulation of the production of reactive oxygen intermediates and anti-apoptotic factors.

To understand the roles of reactive oxygen intermediates (ROI) in Fas-mediated apoptosis of myeloma cells, the effects of antioxidants were tested. Fas-mediated apoptosis was further increased in the presence of antioxidants such as N-acetyl-L-cysteine and glutathione, but it was decreased when hydrogen peroxide was added. The intracellular ROI level was significantly decreased in myeloma cells treated with okadaic acid, an inhibitor of protein phosphatases 1 and 2A (PP1/PP2A). To clarify the direct roles of PP2A in myeloma cell growth, the PP2A transfected cell lines, sense- or antisense-PP2A transfectants, were established. Spontaneous cell growth of antisense-PP2A transfectants was reduced compared with that of vector transfectants. The intracellular ROI level was significantly decreased in antisense-PP2A transfectants but increased in sense-PP2A transfectants compared with vector controls. In addition, anti-apoptotic factors such as bcl-2 and IL-6 were reduced in antisense-PP2A transfectants. Taken together, these results indicate that PP2A is an essential factor for survival and growth of myeloma cells via regulation of intracellular ROI and anti-apoptotic factors.     

HDAC‐inhibitor (S)‐8 disrupts HDAC6‐PP1 complex prompting A375 melanoma cell growth arrest and apoptosis

Histone deacetylase inhibitors (HDACi) are agents capable of inducing growth arrest and apoptosis in different tumour cell types. Previously, we reported a series of novel HDACi obtained by hybridizing SAHA or oxamflatin with 1,4‐benzodiazepines. Some of these hybrids proved effective against haematological and solid cancer cells and, above all, compound (S)‐8 has emerged for its activities in various biological systems. Here, we describe the effectiveness of (S)‐8 against highly metastatic human A375 melanoma cells by using normal PIG1 melanocytes as control. (S)‐8 prompted: acetylation of histones H3/H4 and α‐tubulin; G₀/G₁ and G₂/M cell cycle arrest by rising p21 and hypophos‐phorylated RB levels; apoptosis involving the cleavage of PARP and caspase 9, BAD protein augmentation and cytochrome c release; decrease in cell motility, invasiveness and pro‐angiogenic potential as shown by results of wound‐healing assay, down‐regulation of MMP‐2 and VEGF‐A/VEGF‐R2, besides TIMP‐1/TIMP‐2 up‐regulation; and also intracellular accumulation of melanin and neutral lipids. The pan‐caspase inhibitor Z‐VAD‐fmk, but not the antioxidant N‐acetyl‐cysteine, contrasted these events. Mechanistically, (S)‐8 allows the disruption of cytoplasmic HDAC6‐protein phosphatase 1 (PP1) complex in A375 cells thus releasing the active PP1 that dephosphorylates AKT and blocks its downstream pro‐survival signalling. This view is consistent with results obtained by: inhibiting PP1 with Calyculin A; using PPP1R2‐transfected cells with impaired PP1 activity; monitoring drug‐induced HDAC6‐PP1 complex re‐shuffling; and, abrogating HDAC6 expression with specific siRNA. Altogether, (S)‐8 proved very effective against melanoma A375 cells, but not normal melanocytes, and safe to normal mice thus offering attractive clinical prospects for treating this aggressive malignancy.     

PP4R4/KIAA1622 forms a novel stable cytosolic complex with phosphoprotein phosphatase 4

Protein serine/threonine phosphatase 4 (PP4c) is an essential polypeptide involved in critical cellular processes such as microtubule growth and organization, DNA damage checkpoint recovery, apoptosis, and tumor necrosis factor alpha signaling. Like other phosphatases of the PP2A family, PP4c interacts with regulatory proteins, which specify substrate targeting and intracellular localization. The identification of these regulatory proteins is, therefore, key to fully understanding the function of this enzyme class. Here, using a sensitive affinity purification/mass spectrometry approach, we identify a novel, stable cytosolic PP4c interacting partner, KIAA1622, which we have renamed PP4R4. PP4R4 displays weak sequence homology with the A (scaffolding) subunit of the PP2A holoenzyme and specifically associates with PP4c (and not with the related PP2Ac or PP6c phosphatases). The PP4c.PP4R4 interaction is disrupted by mutations analogous to those abrogating the association of PP2Ac with PP2A A subunit. However, unlike the PP2A A subunit, which plays a scaffolding role, PP4R4 does not bridge PP4c with previously characterized PP4 regulatory subunits. PP4c.PP4R4 complexes exhibit phosphatase activity toward a fluorogenic substrate and gammaH2AX, but this activity is lower than that associated with the PP4c.PP4R2.PP4R3 complex, which itself is less active than the free PP4c catalytic subunit. Our data demonstrate that PP4R4 forms a novel cytosolic complex with PP4c, independent from the complexes containing PP4R1, PP4R2.PP4R3, and alpha4, and that the regulatory subunits of PP4c have evolved different modes of interaction with the catalytic subunit.     

钠泵功能改变及内质网应激在大鼠离体心脏缺血/再灌注损伤中的作用

目的：探讨钠泵活性改变及内质网应激（ERS）在大鼠离体心脏再灌损伤中的作用及其机制。方法：将60只雄性SD大鼠随机分为6组（n=10）：正常对照组（NC组）、缺血/再灌损伤组（I/R组）、哇巴因-缺血/再灌损伤组（OUA-I/R组）、地高辛抗血清-缺血/再灌损伤组（Anti-Dig-I/R组）、Src抑制剂PP2-哇巴因-缺血/再灌损伤组（PP2-OUA-I/R组）、PLC抑制剂U73122-哇巴因-缺血/再灌损伤组（U73122-OUA-I/R组）。建立全心缺血30 min,再灌注120min的Langendorff大鼠离体心脏缺血再灌损伤模型。检测各组相同时间点心功能恢复率、冠脉流出液中乳酸脱氢酶（LDH）和肌酸激酶（CK）活性,心肌中Na⁺-K⁺-ATP酶活性和钙离子水平。流式细胞仪检测心肌细胞凋亡率,Western blot检测心肌钠泵α1亚基、葡萄糖调节蛋白78（GRP78）、C/EBP同源蛋白（CHOP）及凋亡蛋白Bcl-2/Bax的表达。结果：与I/R组相比,给予哇巴因预处理可使心功能恢复率明显下降,心肌酶漏出增多,Na⁺-K⁺-ATP酶的活性降低,心肌细胞内钙水平升高,细胞凋亡率增多,心肌钠泵α1亚基和Bcl-2表达降低,GRP78、CHOP和Bax表达升高;而Anti-Dig-I/R组与I/R组相比各指标均明显改善;给予Src抑制剂PP2或PLC抑制剂U73122后,哇巴因对心肌的损伤作用被部分阻断,表现为心功能恢复率升高,心肌酶漏出减少,Na⁺-K⁺-ATP酶的活性明显恢复,Ca²⁺水平下降,细胞凋亡率下降,心肌钠泵α₁亚基和Bcl-2表达增多,GRP78和Bax表达减少。结论：钠泵功能改变和内质网应激共同参与大鼠离体心脏缺血再灌损伤,钠泵通路（Src和PLC）介导内质网应激是引起大鼠离体心脏缺血再灌损伤细胞凋亡机制之一。     

Characteristics and Purification of PRR1, an RNA Phage Specific for the Broad Host Range Pseudomonas R1822 Drug Resistance Plasmid

A new drug resistance plasmid-dependent RNA containing phage resembling coliphage f2 in its particle size and density is described. The phage, PRR1, will only productively infect some R(+) hosts containing the Pseudomonas drug resistance plasmid R1822. The membrane filter-salt elution patterns, RNase sensitivity, inactivation in low ionic strength solutions, and host range serve to distinguish PRR1 from coliphage f2 and two other Pseudomonas RNA phages, 7s and PP7.     

人IL-12重组逆转录病毒载体在HeLa细胞中的表达

目的:包装携带人白细胞介素12(IL-12)的逆转录病毒,用于宫颈癌的治疗研究.方法:携带IL-12的逆转录病毒重组质粒pL35P40SN经PA317细胞包装,G418筛选.在NIH3T3细胞进行病毒滴度测定.然后用病毒感染人宫颈癌细胞HeLa.PCR、RT-PCR方法检测IL-12基因在HeLa中的整合和表达情况.结果:重组质粒pL35P40SN经PA317细胞包装后收获病毒上清,感染HeLa细胞,检测发现IL-12基因整合到细胞基因组DNA中,并且能有效的转录.结论:成功包装了携带IL-12基因的逆转录病毒,该病毒能有效感染HeLa细胞,并使携带的基因IL-12在细胞中表达,为今后IL-12基因治疗宫颈癌的研究奠定基础.     

Relation between intracellular location and photodynamic efficacy of 5-aminolevulinic acid-induced protoporphyrin IX in vitro. Comparison between human glioblastoma cells and other cancer cell lines.

A promising clinical application of 5-aminolevulinic acid (5-ALA)-induced protoporphyrin IX (PP IX) is fluorescence detection and photodynamic treatment of residual tumour tissue during surgical resection of high grade malignant glioma. U373 MG human glioblastoma cells were used as a model system to study the relation between intracellular location and photodynamic efficacy of 5-ALA-induced PP IX in more detail. Therefore, ultra-sensitive fluorescence microscopy, using either optical excitation of whole cells or selective excitation of the plasma membrane by an evanescent electromagnetic field, was combined with quantitative measurements of intracellular porphyrin amount and phototoxicity. Glioblastoma cells accumulated PP IX to a moderate extent as compared to T47D breast cancer cells (high accumulation) or OV2774 ovarian cancer cells (low accumulation). Although photodynamic inactivation of the different cell lines (decreasing in the order T47D > U373 MG > OV2774) seemed to be directly related to PP IX accumulation, examination of the data in more detail revealed that photodynamic efficacy per photosensitizer molecule (PE) was about two times higher in glioblastoma and ovarian cancer cells as compared to breast cancer cells. The different photodynamic efficacy of PP IX was related to the different intracellular location. In contrast to breast cancer cells where PP IX fluorescence was localized in small granules, PP IX fluorescence in glioblastoma cells and ovarian cancer cells originated mainly from cellular membranes. Thus, the intracellular location of PP IX in a predominantly lipophilic environment, characterized by a comparably high photostability (probed by photobleaching and photoproduct formation) and a lower degree of porphyrin aggregation (probed previously by fluorescence decay kinetics), seems to be the key factor for high photodynamic efficacy of 5-ALA-induced PP IX. In the case of OV2774 ovarian cancer cells, however, a low PP IX accumulation limited cell inactivation upon irradiation, whereas the results obtained for glioblastoma cells are encouraging to develop PDT to an additional therapeutic option for the treatment of tumour margins in patients who underwent fluorescence-guided resection of high grade malignant glioma after 5-ALA administration.